Skip to main content

TESTANDO NUEVAS ESTRATEGIAS PARA TRATAR ENFERMEDADES CEREBRALES ASOCIADAS AL ENVEJECIMIENTO

SAF2016-81716-REDC

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Fomento de la Investigación Científica y Técnica de Excelencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Redes Investigación /Redes Excelencia
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Melatonin induces mechanisms of brain resilience against neurodegeneration.

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Palomera-Ávalos, Verónica
  • Porquet, David
  • García de Frutos, Pablo
  • Franciscato Cozzolino, Silvia M.
  • Rodríguez-Farré, Eduard
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Cardoso, Bárbara R.
Melatonin is an endogenous pleiotropic molecule which orchestrates regulatory functions and protective capacity against age‐related ailments. The increase in circulating levels of melatonin through dietary supplements intensifies its health benefits. Investigations in animal models have shown that melatonin protects against Alzheimer's disease (AD)‐like pathology, although clinical studies have not been conclusive. We hypothesized that melatonin induces changes in the brain that prevent or attenuate AD by increasing resilience. Therefore, we treated healthy nontransgenic (NoTg) and AD transgenic (3xTg‐AD) 6‐month‐old mice with a daily dose of 10 mg/kg of melatonin until 12 months of age. As expected, melatonin reversed cognitive impairment and dementia‐associated behaviors of anxiety and apathy and reduced amyloid and tau burden in 3xTg‐AD mice. Remarkably, melatonin induced cognitive enhancement and higher wellness level‐related behavior in NoTg mice. At the mechanism level, NF‐κB and proinflammatory cytokine expressions were decreased in both NoTg and 3xTg‐AD mice. The SIRT1 pathway of longevity and neuroprotection was also activated in both mouse strains after melatonin dosing. Furthermore, we explored new mechanisms and pathways not previously associated with melatonin treatment such as the ubiquitin‐proteasome proteolytic system and the recently proposed neuroprotective Gas6/TAM pathway. The upregulation of proteasome activity and the modulation of Gas6 and its receptors by melatonin were similarly displayed by both NoTg and 3xTg‐AD mice. Therefore, these results confirm the potential of melatonin treatment against AD pathology, by way of opening new pathways in its mechanisms of action, and demonstrating that melatonin induces cognitive enhancement and brain resilience against neurodegenerative processes., This study was supported by grants SAF2016‐77703‐R, SAF2015‐66515‐R and SAF2016‐81716‐REDC from Spanish MINECO and European Development Fund, and 2017‐SGR‐106 from AGAUR and the CERCA Programme of the Generalitat de Catalunya., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Lack of the aryl hydrocarbon receptor accelerates aging in mice

  • Bravo-Ferrer, Isabel
  • Cuartero, María Isabel
  • Medina, Violeta
  • Ahedo-Quero, Dalia
  • Peña-Martínez, Carolina
  • Pérez-Ruíz, Alberto
  • Fernández-Valle, Encarnación
  • Hernández-Sánchez, Catalina
  • Fernández-Salguero, Pedro M.
  • Lizasoain, Ignacio
  • Moro, María A.
11p.-5 fig.-1 tab., The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor, largely known for its role in xenobiotic metabolism and detoxification as well as its crucial role as a regulator of inflammation. Here, we have compared a cohort wild-type and AhR-null mice along aging to study the relationship between this receptor and age-associated inflammation, termed as "inflammaging," both at a systemic and the CNS level. Our results show that AhR deficiency is associated with a premature aged phenotype, characterized by early inflammaging, as shown by an increase in plasma cytokines levels. The absence of AhR also promotes the appearance of brain aging anatomic features, such as the loss of the white matter integrity. In addition, AhR-/- mice present an earlier spatial memory impairment and an enhanced astrogliosis in the hippocampus when compared with their age-matched AhR+/+ controls. Importantly, we have found that AhR protein levels decrease with age in this brain structure, strongly suggesting a link between AhR and aging.-Bravo-Ferrer, I., Cuartero, M. I., Medina, V., Ahedo-Quero, D., Peña-Martínez, C., Pérez-Ruíz, A., Fernández-Valle, M. E., Hernández-Sánchez, C., Fernández-Salguero, P. M., Lizasoain, I., Moro, M. A. Lack of the aryl hydrocarbon receptor accelerates aging in mice., This work was supported by the Spanish Ministry of Economy and Competitiveness (Grants SAF2015-68632-R and SAF2016-81716-REDC to M.A.M.), Instituto de Salud Carlos III,cofinanced by Fondo Europeo de Desarrollo Regional (FEDER) Una Manera de Hacer Europa (Grants PI17/01601 and RD16/0019/0009 to I.L.), and the Regional Madrid Government (Grant B2017/BMD-3688 to I.L.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Resveratrol Induces Brain Resilience Against Alzheimer Neurodegeneration Through Proteostasis Enhancement

  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Rodríguez-Farré, Eduard
  • Pallàs, Mercè
  • Sanfeliu, Coral
Resveratrol is a natural compound that mimics the antioxidant and antiaging effects of caloric restriction, mainly mediated through SIRT1, a deacetylase that induces longevity and neuroprotection. We aimed to analyze the effects of resveratrol on the brain status of control non-transgenic (NoTg) and AD transgenic (3xTg-AD) mice to discern the mechanisms involved in a potential inducement of resilience against age-related neurodegeneration and Alzheimer’s disease (AD). Mice were fed with a diet supplemented with 100 mg/kg of resveratrol from 2 months of age during 10 months. Resveratrol administration induced complete protection against memory loss and brain pathology in 3xTg-AD mice, and also induced cognitive enhancement in healthy NoTg mice. Resveratrol improved exploration and reduced anxiety in both mouse strains, indicative of well-being. Resveratrol reduced the presence of Aβ and p-tau pathology in the hippocampus of the 3xTg-AD mouse. Proteostasis analysis showed the following in both NoTg and 3xTg-AD mice: (i) increased levels of the amyloid-degrading enzyme neprilysin, (ii) reduction of the amyloidogenic secretase BACE1, and (iii) increase of proteasome protein levels and enhancement of proteasome activity. Resveratrol also increased AMPK protein levels, then upregulating the SIRT1 pathway, as shown by the activation of PGC-1α and CREB in both mice, resulting in further beneficial changes. Our data demonstrated that resveratrol induces cognitive enhancement and neuroprotection against amyloid and tau pathologies. Improvement of proteostasis by resveratrol, in both healthy and AD mice, suggests that it is a mechanism of brain resilience and defense against neurodegeneration caused by the accumulation of aberrant proteins., This study was supported by grants SAF2016-77703 and SAF2016-81716-REDC from Spanish MINECO and European Development Fund; 2017-SGR-106 from AGAUR and the CERCA Programme/Generalitat de Catalunya.